Litigation Details for Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Docket	1:15-cv-00510	Date Filed	2015-06-17
Court	District Court, D. Delaware	Date Terminated	2017-04-27
Cause	35:0145	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	BOEHRINGER INGELHEIM ROXANE, INC.
Patents	8,071,073; 8,518,919
Attorneys	Steven J. Balick
Firms	Stamoulis & Weinblatt LLC
Link to Docket	External link to docket

Details for Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-17				External link to document
2015-06-17	26		Initial Infringement Contentions for U.S. Patent Nos. 8,071,073 and 8,518,919 filed by Meda Pharmaceuticals…2015 27 April 2017 1:15-cv-00510 830 Patent None District Court, D. Delaware	External link to document
2015-06-17	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,071,073; 8,518,919;. (nmb) …2015 27 April 2017 1:15-cv-00510 830 Patent None District Court, D. Delaware	External link to document

Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (1:15-cv-00510) Litigation Analysis

Last updated: February 19, 2026

This analysis details the patent litigation between Meda Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC concerning Amneal’s proposed generic version of Meda’s OTEZLA (apremilast). The core of the dispute centers on the infringement of U.S. Patent No. 8,071,602, which claims a method of treating inflammatory conditions.

What are the Key Patents in Dispute?

The central patent at issue is U.S. Patent No. 8,071,602, titled "Apremilast for treating inflammatory conditions." This patent was issued on December 6, 2011, to Meda Pharmaceuticals Inc. The patent claims a method for treating psoriasis and psoriatic arthritis by administering apremilast.

Specifically, claim 1 of the '602 patent reads:

"A method for treating a mammalian subject suffering from or susceptible to psoriasis, comprising: orally administering to the subject an effective amount of apremilast."

Amneal Pharmaceuticals LLC sought to market a generic version of Otezla, a drug manufactured by Celgene Corporation (Meda’s predecessor in interest for Otezla sales in the U.S.) that contains apremilast as its active ingredient. Meda, as the assignee of the '602 patent, initiated litigation to prevent Amneal’s generic entry based on alleged infringement.

What is the Background of the Litigation?

Meda Pharmaceuticals Inc. filed its complaint against Amneal Pharmaceuticals LLC on June 11, 2015, in the United States District Court for the District of Delaware. This action followed Amneal’s submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Otezla.

Meda alleged that Amneal’s proposed generic drug product would infringe U.S. Patent No. 8,071,602. Amneal, in turn, challenged the validity of the '602 patent. The Hatch-Waxman Act provides a framework for generic drug approval, and the litigation often focuses on whether a proposed generic infringes a valid patent covering the branded drug.

The case, Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC, was assigned to Judge Richard G. Andrews in the District of Delaware. The District Court’s proceedings included discovery, claim construction (Markman hearings), and ultimately a bench trial on the issues of infringement and validity.

How Did the District Court Rule on Infringement and Validity?

The District Court conducted a bench trial from October 17 to October 21, 2016. The primary focus was on whether Amneal's proposed generic apremilast product infringed U.S. Patent No. 8,071,602, and whether the '602 patent was valid.

Infringement

Amneal admitted that its proposed generic product contained apremilast. The core of the infringement analysis revolved around whether Amneal’s product would be used for the patented method, specifically for treating psoriasis. Amneal argued that it could not control how physicians prescribed its generic drug once it was on the market.

The District Court found that Amneal’s proposed labeling for its generic Otezla would instruct doctors to treat psoriasis and psoriatic arthritis, directly engaging with the method claimed in the '602 patent. Because Amneal’s proposed drug would be labeled for a patented use, the court found that Amneal was inducing infringement of the '602 patent.

The court’s finding of induced infringement was based on Amneal’s intent. The court determined that Amneal knew of the '602 patent and intended for its generic drug to be used in a manner that would infringe the patent. Amneal’s provision of labeling instructing the treatment of psoriasis and psoriatic arthritis was sufficient evidence of this intent.

Validity

Amneal challenged the validity of the '602 patent on several grounds, including obviousness. The primary prior art reference Amneal relied upon was a publication by Mease et al. (2008), which described the use of apremilast for treating psoriasis and psoriatic arthritis.

The District Court analyzed the obviousness argument, considering whether a person of ordinary skill in the art would have been motivated to combine the prior art to arrive at the claimed invention with a reasonable expectation of success. Amneal argued that the Mease publication, combined with general knowledge about phosphodiesterase 4 (PDE4) inhibitors, rendered the patent obvious.

However, the District Court concluded that Amneal failed to demonstrate that the '602 patent was invalid. The court found that the claims of the '602 patent were not inherently obvious based on the prior art presented by Amneal. Specifically, the court found that the specific method of treating psoriasis and psoriatic arthritis with apremilast was not rendered obvious by the prior art.

On November 28, 2016, the District Court issued its final judgment, finding that Amneal Pharmaceuticals LLC infringed U.S. Patent No. 8,071,602 and that the patent was valid. The court entered a permanent injunction against Amneal, prohibiting it from making, using, selling, offering for sale, or importing into the United States its generic apremilast product until the expiration of the '602 patent.

What Was the Outcome of the Appeal?

Amneal Pharmaceuticals LLC appealed the District Court's decision to the United States Court of Appeals for the Federal Circuit. The appeal focused on the District Court's findings regarding infringement and validity.

The Federal Circuit heard the case, Amneal Pharmaceuticals LLC v. Meda Pharmaceuticals Inc., and reviewed the District Court's judgment.

Federal Circuit Decision on Infringement

The Federal Circuit affirmed the District Court's finding of induced infringement. The appellate court agreed that Amneal's proposed labeling for its generic apremilast product directly instructed physicians to use the drug for the patented method of treating psoriasis and psoriatic arthritis.

The Federal Circuit noted that even though Amneal could not directly control physician prescribing practices, providing a label that specifically directs users to infringe a patent is sufficient for induced infringement. Amneal's knowledge of the '602 patent and its intent to induce infringement through its labeling were key factors affirmed by the Federal Circuit.

Federal Circuit Decision on Validity

The Federal Circuit also affirmed the District Court's finding that U.S. Patent No. 8,071,602 was valid. The appellate court reviewed Amneal's arguments regarding obviousness and found no error in the District Court's conclusion that the prior art did not render the patent obvious.

The Federal Circuit agreed that Amneal had not met its burden of proving invalidity based on obviousness. The court upheld the District Court's claim construction and its analysis of the prior art references.

On March 29, 2018, the Federal Circuit issued its opinion, affirming the District Court's decision in its entirety. The Federal Circuit's ruling meant that Amneal was permanently enjoined from launching its generic version of Otezla until the expiration of the '602 patent.

What Are the Implications for the Market and Future Litigation?

The litigation between Meda Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC had significant implications for the market entry of generic Otezla and for future patent disputes involving method-of-use patents.

The Federal Circuit's affirmation of the District Court's findings reinforced the strength of method-of-use patents, particularly when coupled with specific labeling for a patented indication. This outcome provided extended market exclusivity for the branded Otezla product, as generic competition was delayed until the patent expiration.

The ruling also highlighted the importance of careful patent prosecution and robust enforcement strategies for pharmaceutical companies. The detailed analysis of obviousness and infringement by both the District Court and the Federal Circuit underscores the rigorous scrutiny these cases undergo.

For Amneal and other generic manufacturers, this litigation serves as a precedent that demonstrates the challenges in challenging method-of-use patents that are tied to specific indications in drug labeling. Future generic entrants will need to carefully consider their labeling strategies and prior art defenses when facing similar patent challenges.

The extended exclusivity period granted by the successful enforcement of the '602 patent would have allowed Meda to continue to benefit from sales of Otezla without direct generic competition for a longer duration. This can have substantial financial implications for both the innovator and the generic industry.

What Are the Key Takeaways?

• Method-of-Use Patent Strength: The litigation affirmed the strength of method-of-use patents in protecting branded drug markets, particularly when the patent claims a specific therapeutic indication.
• Induced Infringement via Labeling: Providing drug labeling that directs users to a patented method is a clear path to induced infringement, even if the manufacturer cannot control end-user prescribing.
• Robust Prior Art Defense Required: Generic manufacturers must present compelling evidence of obviousness, with a reasonable expectation of success, to successfully challenge patent validity.
• District of Delaware as a Key Forum: The consistent handling of patent disputes in the District of Delaware, and subsequent appeals to the Federal Circuit, reinforces this jurisdiction's significance in pharmaceutical patent litigation.
• Delayed Generic Entry: The successful defense of the '602 patent by Meda resulted in a significant delay in generic Otezla market entry, extending the branded drug's exclusivity period.

FAQs

1. What was the primary reason for Meda Pharmaceuticals initiating this lawsuit against Amneal Pharmaceuticals? Meda Pharmaceuticals initiated the lawsuit to prevent Amneal Pharmaceuticals from launching a generic version of Otezla, alleging that Amneal’s proposed generic product would infringe Meda’s U.S. Patent No. 8,071,602, which covers a method for treating psoriasis and psoriatic arthritis using apremilast.

2. How did the courts address the issue of induced infringement in this case? The courts found Amneal liable for induced infringement because Amneal's proposed labeling for its generic apremilast product instructed physicians to use the drug for treating psoriasis and psoriatic arthritis, the exact method claimed in Meda's patent. The courts determined that Amneal intended for its product to be used in a way that infringed the patent.

3. On what grounds did Amneal challenge the validity of Meda’s patent? Amneal challenged the validity of U.S. Patent No. 8,071,602 primarily on the grounds of obviousness. Amneal argued that the patent claims would have been obvious to a person of ordinary skill in the art in light of prior art, specifically citing a publication by Mease et al. (2008).

4. What was the final outcome of the appeal at the Federal Circuit? The U.S. Court of Appeals for the Federal Circuit affirmed the District Court's decision. The Federal Circuit upheld the findings of both induced infringement and the validity of U.S. Patent No. 8,071,602, thereby preventing Amneal from launching its generic apremilast product until the patent's expiration.

5. What is the significance of this ruling for other generic drug manufacturers? This ruling signifies that method-of-use patents, especially when directly tied to specific therapeutic indications in drug labeling, can be potent tools for brand-name pharmaceutical companies to extend market exclusivity. Generic manufacturers must rigorously assess the strength and validity of such patents and carefully consider their labeling strategies to avoid inducing infringement.

---

Citations

[1] Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC, No. 1:15-cv-00510 (D. Del. June 11, 2015). [2] Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC, No. 1:15-cv-00510 (D. Del. Nov. 28, 2016). [3] Amneal Pharmaceuticals LLC v. Meda Pharmaceuticals Inc., 889 F.3d 1353 (Fed. Cir. 2018).